STIM vs. NPCE, DCTH, SMLR, TCMD, CLPT, CVRX, LUNG, ZIMV, SNWV, and NNOX
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include NeuroPace (NPCE), Delcath Systems (DCTH), Semler Scientific (SMLR), Tactile Systems Technology (TCMD), ClearPoint Neuro (CLPT), CVRx (CVRX), Pulmonx (LUNG), ZimVie (ZIMV), SANUWAVE Health (SNWV), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry.
Neuronetics vs.
Neuronetics (NASDAQ:STIM) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 9.8% of Neuronetics shares are owned by insiders. Comparatively, 22.2% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Neuronetics currently has a consensus price target of $5.50, suggesting a potential upside of 45.89%. NeuroPace has a consensus price target of $15.20, suggesting a potential upside of 45.73%. Given Neuronetics' higher possible upside, research analysts plainly believe Neuronetics is more favorable than NeuroPace.
Neuronetics has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.
Neuronetics received 98 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 68.62% of users gave Neuronetics an outperform vote while only 60.78% of users gave NeuroPace an outperform vote.
In the previous week, NeuroPace had 2 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for Neuronetics. NeuroPace's average media sentiment score of 0.47 beat Neuronetics' score of 0.44 indicating that NeuroPace is being referred to more favorably in the news media.
NeuroPace has a net margin of -36.74% compared to Neuronetics' net margin of -50.09%. Neuronetics' return on equity of -141.24% beat NeuroPace's return on equity.
Neuronetics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.
Summary
NeuroPace beats Neuronetics on 12 of the 18 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
This page (NASDAQ:STIM) was last updated on 4/17/2025 by MarketBeat.com Staff
Buy STIM Stock Free STIM Stock Alerts